Aspire Biopharma Holdings, Inc., an early-stage biopharmaceutical company, develops and markets disruptive technology for novel sublingual delivery mechanisms in the United States. It offers Instaprin, a sublingual aspirin product that is a soluble, PH neutral, and fast acting aspirin, which addresses cardiology emergencies and pain management. The company is also developing formulations for sublingually administered products, including a melatonin sleep-aid product; vitamins D, E, and K; testosterone; and semaglutide product. In addition, it is developing formulations for anti-nausea products, anti-psychotic products, ED drugs, seizure medication, and other classes of drugs through sublingual administration; and caffeine products, such as a formula for a single dose sublingual pre-workout supplement. The company was founded in 2021 and is headquartered in Estero, Florida.
Metrics to compare | ASBP | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipASBPPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.4x | −4.7x | −0.5x | |
PEG Ratio | 0.00 | −0.04 | 0.00 | |
Price/Book | −2.7x | 3.8x | 2.6x | |
Price / LTM Sales | - | 1.8x | 3.3x | |
Upside (Analyst Target) | - | 49.0% | 38.7% | |
Fair Value Upside | Unlock | 3.1% | 5.0% | Unlock |